NASDAQ
Incyte Corporation (INCY)
♥ 540 Thanks from members
Incyte Corporation (INCY) faces a mixed market reception following a strong Q2 2026 earnings beat driven by Opzelura's surge, a CMS settlement, and raised guidance, offset by valuation concerns and upcoming 2028 patent cliffs.